April show­ers bring more biotechs to Nas­daq, as Rain and Im­pel bump 2021's to­tal raise above $6B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

What’s that in the sky — is it a bird? Is it a plane? No, it’s an­oth­er hand­ful of biotech IPOs.

Two more biotechs priced their pub­lic of­fer­ings late Thurs­day, com­ing just one day af­ter Zymer­gen blew folks away with its $500 mil­lion pric­ing. This week’s win­ners are Rain Ther­a­peu­tics and Im­pel Neu­rophar­ma, who raised $125 mil­lion and $80 mil­lion, re­spec­tive­ly. Rain priced at $17 and Im­pel’s shares de­buted at $15 apiece.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.